cheaptrix/billsum-US_congress_and_house huggingface dataset:
DEA Enforcement and Authority Act of 2019

To clarify the congressional intent behind the requirements relating to immediate suspension orders and corrective action plans under the Controlled Substances Act that were added by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016. 1. Short title This Act may be cited as the DEA Enforcement and Authority Act of 2019 2. Denial, revocation, or suspension of controlled substances registration (a) Standard of review for immediate suspension orders Section 304(d)(2) of the Controlled Substances Act ( 21 U.S.C. 824(d)(2) a substantial likelihood of an immediate threat probable cause (b) Opportunity To submit corrective action plan prior to revocation or suspension (1) In general Section 304(c) of the Controlled Substances Act ( 21 U.S.C. 824(c) (A) by striking paragraphs (2) through (5); (B) by striking (c)(1) Before (c) Before (C) by adding at the end the following: The order to show cause shall contain a statement of the basis thereof and shall call upon the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but in no event less than 30 days after the date of receipt of the order. Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of chapter 5 (2) Applicability to pending corrective action plans The Attorney General shall not be required to review any corrective action plan submitted by an applicant or registrant under section 304(c)(2) of the Controlled Substances Act ( 21 U.S.C. 824(c)(2)

Summary: DEA Enforcement and Authority Act of 2019 This bill modifies enforcement authorities of the Drug Enforcement Administration (DEA). It modifies the required elements of an order to show cause issued by the DEA before it denies, revokes, or suspends a registration for a CSA violation. Specifically, the bill eliminates the requirement for an order to show cause to notify the registrant of the opportunity to submit a corrective action plan. Additionally, the bill modifies the standard of review for an immediate suspension order. Currently, the DEA may immediately suspend the registration of a controlled substances manufacturer, distributor, or dispenser to prevent imminent danger to the public health and safety. This bill lowers the standard for determining imminent danger to the public health and safety—from substantial likelihood of an immediate threat of harm to probable cause that harm will occur.
Protect Children of Immigrant Workers Act

To protect children of certain immigrant workers from detention and removal and aging out of lawful status, and for other purposes. 1. Short title This Act may be cited as the Protect Children of Immigrant Workers Act 2. Protecting children of certain immigrant workers from detention and removal and aging out of lawful status (a) In general Notwithstanding any other provision of law, subject to subsection (b), with respect to an individual whose parent is the principal beneficiary of an approved employment-based immigrant worker petition filed on a date on which the individual was a child (as defined in section 101(b) of the Immigration and Nationality Act ( 8 U.S.C. 1101(b) (1) the Secretary of Homeland Security shall not detain, refer for removal, initiate removal proceedings against, or remove the individual; and (2) the individual shall— (A) without regard to immigrant intent and on application by the individual, be eligible— (i) to extend nonimmigrant dependent status connected to the nonimmigrant status of such parent until the date on which an application for lawful permanent resident status filed by the individual pursuant to subparagraph (B) is adjudicated; or (ii) to extend or change status to an alternative nonimmigrant status independent of such parent’s visa status until the date on which an application for lawful permanent resident status filed by the individual pursuant to that subparagraph is adjudicated; and (B) qualify as a derivative beneficiary child for immigrant visa purposes beginning on the date on which such parent’s employment-based immigrant worker petition is approved and ending on the date on which the individual’s application for lawful permanent resident status is adjudicated, regardless of whether such parent is living or deceased. (b) Applicability Subsection (a) shall not apply to any individual who the Secretary determines, on an individualized basis, poses a threat to public safety or national security.

Summary: Protect Children of Immigrant Workers Act This bill provides protections for an alien minor whose parent is the principal beneficiary of an employment-based immigrant petition. Specifically, the Department of Homeland Security (DHS) shall not detain or remove such a minor. The minor shall be eligible for nonimmigrant status, either dependent on the parent's status or otherwise, until a decision has been made on the minor's application for lawful permanent resident status. Such a minor shall also qualify as a derivative beneficiary child for immigrant visa purposes starting from the approval of the parent's employment-based immigration petition until a decision has been made on the minor's application for permanent resident status, even if the parent is deceased. These protections shall not apply if DHS determines that the minor poses a threat to public safety or national security.
Protect Access to Birth Control Act

To provide that the rules entitled Religious Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act Moral Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act 1. Short title This Act may be cited as the Protect Access to Birth Control Act 2. Prohibition on certain rules relating to religious and moral exemptions and accommodations for coverage of certain preventive services The Secretary of Health and Human Services, the Secretary of the Treasury, and the Secretary of Labor may not take any action to implement, enforce, or otherwise give effect to the rules entitled Religious Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act Moral Exemptions and Accommodations for Coverage of Certain Preventive Services Under the Affordable Care Act

Summary: Protect Access to Birth Control Act This bill nullifies interim final rules issued by the Department of Labor, the Department of the Treasury, and the Department of Health and Human Services that allow employers with religious or moral objections to be exempt from the requirement that their health insurance plans cover contraceptive services without cost-sharing.
A bill to ensure the protection of human genetic information collected as a result of diagnostic testing for COVID-19.

To ensure the protection of human genetic information collected as a result of diagnostic testing for COVID–19. 1. Protection of human genetic information (a) In general Notwithstanding any other provision of law, the Secretary of Health and Human Services shall ensure that no person may collect, store, analyze, disseminate, or otherwise make use of, or benefit from, any human genetic information collected as a result of diagnostic testing for COVID–19, for any incidental use, or any reason other than such diagnostic or serologic testing, except with the express, written, informed consent of the individual being tested. (b) Enforcement Any person who violates subsection (a) shall be subject to a civil monetary penalty of not more than $100 for each such violation. (c) Definitions In this section— (1) the term genetic information (2) the term incidental

Summary: This bill prohibits the use of genetic material collected as a result of a COVID-19 (i.e., coronavirus disease 2019) test for any other purpose without the written, informed consent of the individual being tested. A person who violates this prohibition is subject to a civil monetary penalty of not more than $100 for each violation.
Second Look at Drug Patents Act of 2020

To amend the Federal Food, Drug, and Cosmetic Act with respect to the listing of patents in the Orange Book. 1. Short title This Act may be cited as the Second Look at Drug Patents Act of 2020 2. Amendments Section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 (1) in subsection (b)(1), in the fifth sentence, by inserting , subject to the conditions under subsection (j)(7)(A)(iii)(II) being met (2) in subsection (c)(2), at the end of the third sentence, by inserting subject to the conditions under subsection (j)(7)(A)(iii)(II) being met (3) in subsection (j)(7)(A)(iii)— (A) by striking When patent (I) When patent (B) by inserting , subject to subclause (II), , include (C) by adding at the end the following: (II) The Secretary shall include patent information on the list pursuant to subclause (I) if the following conditions are met: (aa) If the patent has been issued as of the date on which the application is approved under subsection (c), the sponsor, within 30 days of the date of such approval, shall submit to the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (referred to in this clause as the Director (bb) If the patent is issued after the date on which the application is approved under subsection (c), the sponsor, not later than 30 days after the date on which the patent is issued, shall submit to the Director a notification that the sponsor has filed with the Secretary information about the patent as required under subsection (c)(2). (cc) Upon receipt of a notification under item (aa) or (bb), as applicable, the Director shall publish, not later than 30 days of such receipt, in the Official Gazette of the United States Patent and Trademark Office, and on an internet website that the Director shall establish, maintain, and operate, a notification with respect to the patent, requesting that any person that is eligible to file a request described in section 311(b) of title 35, United States Code, file such a request. .

Summary: Second Look at Drug Patents Act of 2020 This bill imposes additional patent reporting requirements on the manufacturers of certain drugs approved by the Federal Drug Administration.
No Funds to China's Military Act of 2020

To prohibit the use of funds to purchase goods or services from Communist Chinese military companies. 1. Short title This Act may be cited as the No Funds to China’s Military Act of 2020 2. Prohibition on use of funds to purchase goods or services from Communist Chinese military companies (a) In general None of the funds authorized to be appropriated or otherwise made available for fiscal year 2020 and available for obligation as of the date of the enactment of this Act, or authorized to be appropriated or otherwise made available for fiscal year 2021 or any fiscal year thereafter, may be obligated or expended to purchase goods or services from a person on the list required by section 1237(b) of the Strom Thurmond National Defense Authorization Act for Fiscal Year 1999 ( Public Law 105–261 50 U.S.C. 1701 (b) Application to private entities and State and local governments (1) In general The prohibition under subsection (a) includes a prohibition on the obligation or expenditure of funds described in that subsection for the purchase of goods or services from persons described in that subsection by a private entity or a State or local government that received such funds through a grant or any other means. (2) Certification required to receive future funds On and after the date of the enactment of this Act, the head of an executive agency may not provide funds described in subsection (a) to a private entity or a State or local government unless the entity or government certifies that the entity or government, as the case may be, is not purchasing goods or services from a person described in subsection (a). (c) Executive agency defined In this section, the term executive agency

Summary: No Funds to China's Military Act of 2020 This bill prohibits using federal funds to purchase goods or services from an individual or entity that the Department of Defense has determined is controlled by or affiliated with China's military or defense industrial base. This prohibition applies to federal funds provided to a state or local government or private entity. Before an executive agency provides federal funds to such a government or private entity, the recipient shall certify that it will comply with this bill.
Secure Our Transit Systems from Chinese Interference Act

To repeal the temporary exemption to the certification requirement under section 5323 of title 49, United States Code, for contracts between public transportation agencies and rolling stock manufacturers. 1. Short title This Act may be cited as the Secure Our Transit Systems from Chinese Interference Act 2. Limitation on certain rolling stock procurements Section 5323(u)(5) of title 49, United States Code, is amended— (1) by striking (A) Parties to executed contracts (2) by striking subparagraphs (B) and (C).

Summary: Secure Our Transit Systems from Chinese Interference Act This bill eliminates the temporary exemption to certification requirements for the procurement of rail rolling stock for use in public transportation with respect to contracts between public transportation agencies and certain rolling stock manufacturers. Such manufacturers include ones that are owned or controlled by, are a subsidiary of, or otherwise are related legally or financially to a corporation based in a country that (1) is identified as a nonmarket economy country, (2) was identified by the Office of the United States Trade Representative (USTR) as a foreign country included on the priority watch list, and (3) is subject to monitoring by the USTR.
Long-Term Care Pharmacy Definition Act of 2020

To codify a statutory definition for long-term care pharmacies. 1. Short title This Act may be cited as the Long-Term Care Pharmacy Definition Act of 2020 2. Definition Section 1860D–2 of the Social Security Act ( 42 U.S.C. 1395w–102 (f) Long-Term care pharmacy defined (1) In general The term long-term care pharmacy (2) Enhanced pharmacy and clinical services As used in this subsection, the term enhanced pharmacy and clinical services (A) medications dispensed pursuant to a prescription or chart order in specialized packaging which shall include unit of use packaging, unit dose packaging, single use containers, packaging from remote automated dispensing technology, or other packaging required; (B) drug utilization review to identify potential adverse drug reactions and inappropriate drug usage; (C) medication reconciliation services at the transition of care and other necessary clinical management and medication services; (D) timely medication delivery 24 hours a day, 7 days a week; (E) pharmacist on-call availability to provider dispensing and clinical services 24 hours a day, 7 days a week; (F) emergency supplies of medication as permitted by law and as required, including emergency kits or remote automated dispensing technology at a facility; and (G) such other services as the Secretary determines appropriate. (3) Individuals requiring enhanced medication services As used in this subsection, the term individual who requires enhanced medication services (4) Facility As used in this subsection, the term facility .

Summary: Long-Term Care Pharmacy Definition Act of 2020 This bill establishes a statutory definition for long-term care pharmacy under the Medicare prescription drug benefit. Currently, there is no statutory definition. Regulations from the Centers for Medicare & Medicaid Services (CMS) define a long-term care pharmacy as a pharmacy that is owned by or under contract with a long-term care facility to provide prescription drugs to the facility's residents. Additional requirements are set out in CMS guidance relating to the Medicare prescription drug benefit; pharmacies are also subject to regulations and guidance from other agencies (e.g., packaging requirements from the Food and Drug Administration).     The bill defines a long-term care pharmacy as a state-licensed pharmacy that is able to provide enhanced pharmacy and clinical services to individuals who have certain comorbid and medically complex chronic conditions and who reside in skilled nursing facilities, nursing facilities, or any other applicable setting (as determined by the CMS). The term enhanced pharmacy and clinical services includes medication dispensed in special packaging, drug utilization review, and 24-7 availability of medication delivery and on-call pharmacists.
FAIR Act

To increase the rates of pay under the General Schedule and other statutory pay systems and for prevailing rate employees by 3.6 percent, and for other purposes. 1. Short title This Act may be cited as the Federal Adjustment of Income Rates Act of 2019 FAIR Act 2. Adjustment to rates of pay (a) Statutory pay systems The adjustment in rates of basic pay for employees under the statutory pay systems (as defined in section 5302 of title 5, United States Code) that takes effect in fiscal year 2020 under section 5303 of title 5, United States Code, shall be an increase of 3.6 percent, and such adjustments shall be effective as of the first day of the first applicable pay period beginning on or after January 1, 2020. (b) Prevailing rate employees The adjustment in rates of basic pay for the statutory pay systems that take place in fiscal year 2020 under sections 5344 and 5348 of title 5, United States Code, shall be equal to the percentage adjustment received by employees in the same location whose rates of basic pay are adjusted pursuant to the statutory pay systems under subsection (a) of this section and 5304 of title 5, United States Code. Prevailing rate employees at locations where there are no employees whose pay is increased pursuant to sections 5303 and 5304 of title 5 and prevailing rate employees described in section 5343(a)(5) of title 5, United States Code, shall be considered to be located in the pay locality designated as Rest of US

Summary: Federal Adjustment of Income Rates Act of 2019 or the FAIR Act This bill increases by 3.6% in FY2020 the rates of basic pay for federal employees under the statutory pay systems (i.e., the General Schedule, the Foreign Service Schedule, and various schedules related to the Veterans Health Administration) and for prevailing rate employees.
Employer Assistance Coordination Act

To improve coordination between the paycheck protection program and employee retention tax credit. 1. Short title This Act may be cited as the Employer Assistance Coordination Act 2. Improved coordination between paycheck protection program and employee retention tax credit (a) Amendment to paycheck protection program Section 1106(a)(8) of the CARES Act ( Public Law 116–136 , except that such costs shall not include qualified wages taken into account in determining the credit allowed under section 2301 of this Act (b) Amendments to employee retention tax credit (1) In general Section 2301(g) of the CARES Act ( Public Law 116–136 (g) Election To not take certain wages into account (1) In general This section shall not apply to qualified wages paid by an eligible employer with respect to which such employer makes an election (at such time and in such manner as the Secretary may prescribe) to have this section not apply to such wages. (2) Coordination with paycheck protection program The Secretary, in consultation with the Administrator of the Small Business Administration, shall issue guidance providing that payroll costs paid or incurred during the covered period shall not fail to be treated as qualified wages under this section by reason of an election under paragraph (1) to the extent that a covered loan of the eligible employer is not forgiven by reason of a decision under section 1106(g). Terms used in the preceding sentence which are also used in section 1106 shall have the same meaning as when used in such section. . (2) Conforming amendments (A) Section 2301 of the CARES Act ( Public Law 116–136 (B) Section 2301(l) of the CARES Act ( Public Law 116–136 (c) Effective date The amendments made by this section shall take effect as if included in the provisions of the CARES Act ( Public Law 116–136

Summary: Employer Assistance Coordination Act This bill permits certain small employers who participate in the Payroll Protection Program established to assist such employers adversely affected by the COVID-19 (i.e., coronavirus disease 2019) public health emergency to also claim the refundable employee retention tax credit if their businesses have experienced a significant reduction in revenue or have closed pursuant to a government order. The bill prohibits employers from using funds from both programs based upon the same wages paid to their employees.
A bill to amend the CARES Act to ensure that the temporary relief from CECL standards does not terminate in the middle of a company's fiscal year.

To amend the CARES Act to ensure that the temporary relief from CECL standards does not terminate in the middle of a company’s fiscal year. 1. Temporary relief from CECL standards Section 4014(b) of the CARES Act ( Public Law 116–136 ending on the earlier of ending on the first day of the fiscal year of such insured depository institution, bank holding company, or any affiliate that begins after the date on which the national emergency concerning the novel coronavirus disease (COVID–19) outbreak declared by the President on March 13, 2020, under the National Emergencies Act ( 50 U.S.C. 1601

Summary: This bill modifies the delay for required compliance with certain accounting standards applicable to credit losses (i.e., current expected credit losses standards, also known as CECL standards) as applied to insured depository institutions and bank holding companies. Specifically, required compliance with this standard is delayed through the first day of an institution's fiscal year beginning after the end of the emergency declaration regarding the COVID-19 (i.e., coronavirus disease 2019) outbreak. Currently, this delay ends the earlier of the date on which the emergency declaration terminates, or December 31, 2020.